Andrew A. Y. Chen

Andrew A. Y. Chen

Auto-generated profile, based on publicly available information

Andrew A. Y. Chen

Department of Biochemistry and Molecular Biology, Dalhousie University Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Halifax Nova Scotia Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
RSRichard Schwarzkopf
Richard Schwarzkopf
ACAndrew A.Y. Chen
Andrew A.Y. Chen
SQStephanie Quon
Stephanie Quon
JVJulia Varghese
Julia Varghese
JRJanet Helen Roberts
Janet Helen Roberts
LCLuke Y.C. Chen
Luke Y.C. Chen
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.

31 March 2026 in Acta Biomaterialia
Verified
Journal Article
Open access
AGAnupama Ghimire
Anupama Ghimire
SLSae Yeon Lee
Sae Yeon Lee
ACAndrew A.Y. Chen
Andrew A.Y. Chen
YTYanitza Trosel
Yanitza Trosel
JFJohn P. Frampton
John P. Frampton
JRJan Rainey
Jan Rainey
Spider silks are renowned for exceptional mechanical properties and as promising biomaterials. Here, we introduce a recombinant chimeric protein (W2Cma2ap-55) composed of two aciniform silk repetitive units (W2), a major ampullate silk non-repetitive C-terminal domain (Cma2), and the human peptidic G-protein-coupled receptor (GPCR) ligand apelin-55 (ap-55). Ap-55 is an endogenous apelin receptor (AR) ligand, regulating various natural and pathological processes and with noted potential for therapeutic targeting. W2Cma2ap-55 expressed in Escherichia coli proved amenable to both film and fiber formation, with the protein lacking ap-55 (W2Cma2) used as a control throughout. Films and fibers formed from W2Cma2ap-55 were recognized by an anti-apelin antibody, in contrast to W2Cma2, confirming ap-55 accessibility and intactness. Compared to W2Cma2 fibers, W2Cma2ap-55 fibers exhibited comparable extensibility alongside enhanced strength and toughness. Films prepared from both W2Cma2ap-55 and W2Cma2 were non-cytotoxic to HEK 293A cells stably transfected with the AR. Growth of these cells on W2Cma2ap-55 films increased ERK phosphorylation relative to either W2Cma2 or non-silk substrate conditions, consistent with ap-55-induced AR activation. Cell attachment was also observed on the surface of W2Cma2ap-55 fibers. W2Cma2ap-55 is thus a promising engineered protein capable of supporting cell growth and eliciting GPCR signaling. STATEMENT OF SIGNIFICANCE: Spider silks form protein-based fibers renowned for withstanding high force and extension before breaking and for potential in biomedical application, with use of natural spider silks as sutures dating back thousands of years. Here, we introduce an engineered spider silk protein with an extension targeting a specific human cell surface receptor, the apelin receptor. This protein forms transparent films and strong and flexible fibers, supporting growth and attachment of human cells. The functionalized silk also promotes signaling in cells with the apelin receptor, while cells without it are unaffected. These new silk materials thus have enhanced functionality, allowing targeted cell signaling in the laboratory setting with potential for future application in tissue culture or biomedical device development.

22 April 2026 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
ACAndrew A. Y. Chen
Andrew A. Y. Chen
RSRichard Schwarzkopf
Richard Schwarzkopf
KSKasmintan A. Schrader
Kasmintan A. Schrader
LCLuke Y. C. Chen
Luke Y. C. Chen